US FDA Provides Reminders for Upcoming eCTD Validation Changes

Posted by Cary Smithson | Mar 2, 2022 5:39:45 PM

The DIA Regulatory Submissions, Information, and Document Management (RSIDM) Forum, held online and in person from February 14 to 16, was packed with practical information. It was great to catch up with colleagues from across the industry and share our perspectives and practices. As always, the Ask the Regulators Sessions were well-attended and full of practical questions and thoughtful responses. The presentation by US FDA’s Jonathan Resnick, Project Management Officer from the Office of Business Informatics, Center for Drug Evaluation and Research, offered great practical reminders of imminent changes that will impact submissions starting next month.  

In his Electronic Submissions Update, Resnick reminded the audience about two significant short-term changes that will become effective March 1, 2022.  

eCTD Module 1 Specification 

The first change relates to the updated eCTD Module 1 specification. Effective March 1, 2022, the Module 1 DTD v2.01 will no longer be supported at the agency. All US submissions must use DTD v3.3 to pass validation. The new version of the DTD supports grouped submissions and other updates.  

eCTD Validation Errors 

The second impending change relates to two critical validation errors that will be elevated to a higher severity level.  

Effective March 1, 2022, the FDA will reject any submissions that fail validation #1306 and #1323. Error 1306 refers to “no leaf element for file” and error 1323 refers to “no file for leaf element.” Currently, both errors trigger warnings that CDER includes in the electronic submission gateway (ESG) 3rd acknowledgment. Starting March 1, any submission that receives these errors will be rejected.  

The 1306 error creates an issue for reviewers because files are not referenced in the eCTD backbone. These files cannot be easily identified or accessed by the FDA’s systems that use the backbone information to present submission content or by FDA reviewers. The errors represent .25% of the total submissions processed. Still, the concern relates to critical data that reviewers won’t know exists because they cannot access it.  

The 1323 error represents .49% of the total submissions processed. Again, this may seem like a minor issue, given the number of submissions that generate the error. However, the concern is similar in that it appears that a file is in the submission, but reviewers and the FDA’s systems cannot identify it.  

eCTD Compilation and Validation Practices 

Sponsors should be transitioning now to the new version of the Module 1 specification. They should be paying close attention to the validation errors. The small percentage of errors noted by the FDA will be of little consolation if your submission is rejected.  

If you have any questions or concerns about your company’s regulatory submissions related to these changes, request a meeting with one of our regulatory experts. 

Topics: eCTD

Rewind the clock and take TMF back to basics

Rewind the clock and take TMF back to basics: The paradigm of maintaining simplicity while embracing technology. In 20 ...

Read More

How to Reduce Risk and Effort When Migrating a Trial Master File

Migrating Trial Master File (TMF) data is a fairly common occurrence, usually driven by one or more of the following ...

Read More

Consistency: The Secret to Improving Quality and Efficiency in TMF Document Processing

Based on extensive work helping trial sponsors and Contract Research Organizations (CROs) implement Trial Master File ...

Read More

Solved: Is Our TMF Missing More than We Know?

In a poll of nearly 100 TMF professionals during a recent Phlexglobal webinar, “Lowering your TMF Risk Temperature: ...

Read More

How Risk-Based TMF Quality Checks and Quality Review Improve Inspection-Readiness

For the kickoff of Phlexglobal’s “TMF Summer Shorts” program July 18, 2023, we purposely chose a hot topic: how to ...

Read More

Building a Strong Sponsor-CRO Relationship for an Inspection-ready TMF

Collaborative sponsor-contract research organization (CRO) relationships can be the key to ensuring outsourced clinical ...

Read More

Subscribe To Our Blog!

Digital Brain Header Large Brain Right

It's time to raise your standard 

Contact Us